Chapter 46: Antiulcer & Acid-Reducing Drugs

Antiulcer & Acid-Reducing Drugs begins by establishing the pathophysiology of ulceration, which arises from an imbalance between aggressive factors, such as the hypersecretion of hydrochloric acid and pepsin, and defensive mechanisms like the gastric mucosal barrier and sphincter competency. A significant portion of the text is dedicated to the identification and eradication of Helicobacter pylori, a gram-negative bacterium responsible for a high percentage of gastric and duodenal ulcers. The summary outlines specific multi-drug protocols, often termed triple or quadruple therapy, which combine antibiotics (such as metronidazole, clarithromycin, or amoxicillin) with acid-suppressing agents like proton pump inhibitors to prevent bacterial resistance and ensure effective eradication. The chapter details seven distinct categories of antiulcer agents, explaining their pharmacodynamics, pharmacokinetics, and nursing considerations. Tranquilizers and anticholinergics are briefly discussed for their ability to reduce vagal stimulation and delay gastric emptying, though their use has declined due to side effects. A substantial section covers antacids, differentiating between systemic types like sodium bicarbonate and calcium carbonate—which carry risks of metabolic alkalosis and Burnett syndrome—and nonsystemic agents containing aluminum or magnesium hydroxides, which are often combined to balance constipation and diarrhea side effects. The text further explores Histamine-2 (H2) blockers, such as famotidine and cimetidine, which inhibit acid secretion by blocking H2 receptors on parietal cells, noting the superior potency and safety profile of newer agents compared to cimetidine. Proton Pump Inhibitors (PPIs), including omeprazole, lansoprazole, and pantoprazole, are examined as the most potent acid suppressors, inhibiting the hydrogen-potassium ATPase enzyme system to treat severe conditions like Zollinger-Ellison syndrome and erosive esophagitis. Additionally, the summary reviews mucosal protective agents like sucralfate, a pepsin inhibitor that forms a viscous barrier over the ulcer crater, and prostaglandin analogues like misoprostol, which are specifically indicated for preventing ulcers induced by nonsteroidal antiinflammatory drugs (NSAIDs). The content concludes by integrating the nursing process, stressing the importance of nonpharmacologic measures such as dietary modifications, smoking cessation, and stress management to prevent disease recurrence.